cefovecin and Cat-Diseases

Cefovecin is a third-generation cephalosporin antibiotic with an efficacy of 2 wk following a single injection in domestic dogs and cats. A high degree of plasma protein binding to cefovecin has been proposed as one of the mechanisms responsible for the long elimination half-life, but protein binding has not been evaluated extensively in nondomestic species. In this study, a review of the current literature was conducted, and pharmacokinetic data were compiled for species in which cefovecin has been evaluated thus far. Additionally, in vitro cefovecin protein binding was evaluated in plasma from 22 nondomestic species representing a broad range of taxa. Animals of the order Carnivora demonstrated protein-binding levels of >98%, which is supportive of the long elimination half-life seen in related species. Protein binding was highly variable in Artiodactyl and Perissodactyl species, with dolphins (

Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cephalosporins; Dog Diseases; Dogs; Injections, Subcutaneous; Protein Binding

To compare efficacy of amoxicillin-clavulanic acid, cefovecin, and doxycycline in shelter-housed cats with clinical signs of upper respiratory tract disease (URTD).. Randomized prospective clinical trial. Animals-48 cats with URTD.. Conjunctival and nasal swab specimens were obtained for culture and susceptibility testing, and cats were randomly assigned to 3 treatment groups (16 cats/group) on day 1: amoxicillin-clavulanic acid (12.5 mg/kg [5.68 mg/lb], PO, q 12 h, for 14 days), cefovecin (8.0 mg/kg [3.64 mg/lb], SC, once), or doxycycline (10.0 mg/kg [4.55 mg/lb], PO, q 24 h, for 14 days). Oculonasal discharge, sneezing, coughing, dyspnea, demeanor, and food intake were scored twice daily for 14 days (scale, 0 [subjectively normal] to 3 [markedly abnormal]).. The most common bacterial isolates were Mycoplasma spp (n = 22) and Bordetella bronchiseptica (9). Cats treated with amoxicillin-clavulanic acid or doxycycline had significantly increased body weight by day 14. Cats that received doxycycline had significantly lower overall oculonasal discharge scores than those treated with amoxicillin-clavulanic acid or cefovecin. Cats treated with amoxicillin-clavulanic acid or doxycycline had significantly lower overall sneezing scores than those that received cefovecin. Cats that received amoxicillin-clavulanic acid had significantly decreased demeanor and food intake scores on day 2, whereas this was detected later in other groups (demeanor score on days 5 and 7 and food intake score on days 10 and 11 in the cefovecin and doxycycline groups, respectively).. Oral administration of amoxicillin-clavulanic acid or doxycycline appeared to be more effective than a single SC injection of cefovecin in treating cats with clinical signs of URTD.

Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cephalosporins; Doxycycline; Drug Administration Schedule; Female; Housing, Animal; Male; Respiratory Tract Infections

To evaluate the effectiveness and safety of cefovecin sodium in the treatment of cats with naturally occurring skin infections (abscesses and infected wounds).. Multicenter (26 sites), randomized, double-blind, controlled clinical trial.. Client-owned cats of any breed with naturally occurring skin infections with associated clinical signs and confirmatory bacteriologic culture results.. Cats with clinical signs of skin and soft tissue infection were randomly allocated to receive a single dose of cefovecin (8 mg/kg [3.6 mg/lb], SC) followed by placebo drops administered orally once daily for 14 days or 1 SC placebo injection followed by cefadroxil (22 mg/kg [10 mg/lb], PO, once daily for 14 days). Only one 14-day treatment course was permitted.. Effectiveness of cefovecin in the treatment of cats with abscesses and infected wounds was similar to that of cefadroxil. At the final assessment on day 28, 97% (86/89) of cefovecin-treated cats and 91% (80/88) of cefadroxil-treated cats were considered treatment successes. There were no serious adverse events or deaths related to treatment.. 1 SC injection of 8 mg of cefovecin/kg for the treatment of cats with naturally occurring skin infections (wounds and abscesses) was safe and as effective as cefadroxil administered orally at 22 mg/kg, once daily for 14 days.

Topics: Abscess; Administration, Oral; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cephalosporins; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Microbial Sensitivity Tests; Safety; Treatment Outcome; Wound Infection

To determine the efficacy and safety of cefovecin (Convenia); Pfizer Animal Health) in the treatment of urinary tract infections in cats.. A multi-centre, masked, randomised study was conducted in cats presenting with clinical signs indicative of urinary tract infections. Cephalexin (Rilexine); Virbac) administered orally twice daily at 15 mg/kg bodyweight for 14 days was compared with a single subcutaneous injection of cefovecin in cats. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.. Four hundred and thirty-four cats were screened for urinary tract infections. One hundred and eighty-five cats were treated with either cefovecin (n=124) or cephalexin (n=61). Ninety-seven cats (22.2 per cent) had confirmed bacteriuria and 82 cats were included in efficacy analysis. Escherichia coli was eliminated in 76.7 per cent (23 of 30) of cefovecin-treated cats compared with 62.5 per cent (10 of 16) of cephalexin-treated cats. Cefovecin demonstrated statistical non-inferiority compared with cephalexin for bacterial elimination. There were no suspected adverse drug reactions attributable to treatment with cefovecin or cephalexin.. Cefovecin was demonstrated to be an effective and safe treatment for urinary tract infections.

Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cephalosporins; Double-Blind Method; Escherichia coli Infections; Female; Injections, Subcutaneous; Male; Safety; Treatment Outcome; Urinary Tract Infections

To determine the efficacy and safety of cefovecin for the treatment of bacterial abscesses and wounds in cats at clinics in Germany, France, Spain and the UK.. Cats with abscesses or wounds were enrolled. Cats (217) were randomised to treatment with either cefovecin administered by subcutaneous injection at 14 day intervals or amoxicillin/clavulanic acid as twice-daily oral tablets for 14 days. Treatment courses were repeated at 14 day intervals, when deemed necessary. Clinicians assessing lesions were masked to treatment allocation. Only animals with a confirmed pretreatment bacterial pathogen were included in the efficacy analysis. Cases were evaluated 28 days after initiation of the final course of treatment.. Cefovecin was as efficacious as amoxicillin/clavulanic acid, and efficacy was 100 per cent for both treatments.. Cefovecin, administered as a single subcutaneous injection repeated at 14 day intervals as required, was shown to be as efficacious as oral amoxicillin/clavulanic acid in the treatment of abscesses/wounds in cats.

Topics: Abscess; Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Cephalosporins; Clavulanic Acid; Europe; Female; Injections, Subcutaneous; Male; Treatment Outcome; Wound Infection

To understand veterinarian and cat owner perspectives on antimicrobial use in cats, reasons for prescribing cefovecin, and barriers to improving antimicrobial stewardship, including veterinarian and cat owner perspectives of giving oral medication to cats.. 21 New York veterinarians and 600 cat owners across the US.. Cat owners were surveyed about their preferences for and experiences in giving oral medications to cats and their experiences with antimicrobials specifically. Veterinarians were interviewed about antimicrobial use decisions in cats, benefits and drawbacks of cefovecin, and their perspectives on antimicrobial resistance.. Many veterinarians reported feeling pressure to prescribe antimicrobials, while 41% of cat owners reported requesting antimicrobials. Although veterinarians are aware of the downsides of prescribing cefovecin, many prescribed cefovecin in situations where an antimicrobial was not needed or cefovecin may not have been the best choice. Veterinarians thought that 20% of cat owners could not give oral medications, but < 10% of cat owners had a cat that was impossible to medicate.. The disconnect between veterinarians' assessment of and cat owners' reported abilities in administering oral medication may contribute to cefovecin use. Demonstrating for cat owners how to give oral medication may help improve compliance and reduce the use of parenteral long-acting formulations. Structural and educational interventions are needed to address other contributors to inappropriate antimicrobial use. This research provides the specific considerations about barriers and motivations for cat owners and veterinarians that are required to guide strategic, tailored interventions for both audiences to advance stewardship.

Topics: Animals; Anti-Infective Agents; Cat Diseases; Cats; Cephalosporins; Humans; Surveys and Questionnaires; Veterinarians

Cefovecin is a long-acting third-generation cephalosporin commonly used in veterinary medicine. Third-generation cephalosporins are critically important antimicrobials that should only be used after culture and susceptibility testing. The authors describe the common indications for cefovecin use in dogs and cats, and the frequency of culture and susceptibility testing.. A cross-sectional study was performed using clinical records extracted from VetCompass Australia. A previously described method was used to identify records containing cefovecin. The reason for cefovecin use was annotated in situ in each consultation text.. Over a six-month period (February and September 2018), 5180 (0.4 per cent) consultations involved cefovecin administration, of which 151 were excluded. Cats were administered cefovecin more frequently than dogs (1.9 per cent of cat consultations and 0.1 per cent of dog consultations). The most common reasons for cefovecin administration to cats were cat fight injuries and abscesses (28 per cent) and dermatitis (13 per cent). For dogs, the most common reasons for cefovecin administration were surgical prophylaxis (24 per cent) and dermatitis (19 per cent). Culture and susceptibility testing were reported in 16 cases (0.3 per cent).. Cefovecin is used in many scenarios in dogs and cats where antimicrobials may be either not indicated or where an antimicrobial of lower importance to human health is recommended.

Topics: Animals; Australia; Cat Diseases; Cats; Cephalosporins; Cross-Sectional Studies; Culture Techniques; Dog Diseases; Dogs; Female; Hospitals, Animal; Male; Microbial Sensitivity Tests

feline plasmacytic gingivostomatitis is an important and fairly common chronic disease. Its complex aetiology - which involves infectious agents, immunological disorders, and even genetic factors adds to the considerable difficulty of its treatment.. the study was performed on 33 cats, 26 animals diagnosed with plasmacytic gingivostomatitis (study group) and 7 clinically healthy cats (control group). The study extended over four examination periods during which clinical and X-ray examinations, morphological and biochemical blood tests, as well as haptoglobin essays were performed.. the biochemical and haematological parameters were within normal limits. Blood serum haptoglobin measured on the first day of the treatment was above physiological levels, however its serum concentration decreased as the treatment progressed.. in the present study, despite the bacterial inflammatory condition of periodontal pockets, after the treatment was concluded and symptoms alleviated, neither clinical examinations nor haptoglobin essays revealed deviations from values commonly accepted as normal. Fluctuations in blood serum haptoglobin levels proved to be a useful prognostic in determining the duration of necessary treatment.

Topics: Animals; Anti-Bacterial Agents; Biomarkers; Cat Diseases; Cats; Cephalosporins; Dental Care; Female; Gentamicins; Haptoglobins; Male; Prednisolone; Stomatitis

Objectives The objective was to use electronic health records to describe the use of cefovecin (Convenia; Zoetis UK), a third-generation long-acting injectable antimicrobial, in a UK population of cats attending first-opinion practices, and to compare the use of Convenia with the licensed uses described on the UK Convenia datasheet. Methods Data were obtained as an Excel database from the Small Animal Veterinary Surveillance Network for all feline consultations containing the word Convenia and/or cefovecin from 1 September 2012 to 23 September 2013 inclusive. Entries were classified according to body system treated, confirmation or suspicion of an abscess, evidence of microbiological evaluation being performed, any concurrent therapies given and whether any reason was given for use of Convenia over alternative antimicrobials. Data were exported to IBM SPSS Statistics and descriptive analysis performed. Results In total, 1148 entries were analysed. The most common body system treated was skin in 553 (48.2%) entries, then urinary (n = 157; 13.7%) and respiratory (n = 112; 9.8%). Microbiological evaluation was recorded in 193 (16.8%) entries, with visible purulent material most commonly cited (in 147 [12.8%] entries). A reason for prescribing Convenia over alternative antimicrobials was given in 138 (12.0%) entries; the most cited was an inability to orally medicate the cat in 77 (55.8%) of these entries. Excluding 131 entries where no body system or multiple body systems were described, the use of Convenia complied with a licensed use in the UK datasheet in 710 (69.8%) of 1017 entries. Conclusions and relevance Most administrations were licensed uses; however, most entries did not describe any microbiological evaluation, or a reason for prescribing Convenia over alternative antimicrobials. Further education of the public and the veterinary profession is needed to promote antimicrobial stewardship in the UK. Health records provide a valuable tool with which to monitor, both locally and at scale, the use of important therapeutics like antimicrobials. Information relevant to decision-making should be recorded in individual animal health records.

Topics: Abscess; Animals; Anti-Bacterial Agents; Bacterial Infections; Cat Diseases; Cats; Cephalosporins; Databases, Factual; Female; Male; Practice Patterns, Physicians'; United Kingdom; Veterinary Drugs

Periodontal disease is a common disease of dogs and cats often requiring antimicrobial treatment as an adjunct to mechanical debridement. However, correct compliance with oral antimicrobial therapy in companion animals is often difficult. Cefovecin is a recently introduced veterinary cephalosporin that has demonstrated prolonged concentrations in extracellular fluid, allowing for dosing intervals of up to 14 days. Subgingival samples were collected from the oral cavity of 29 dogs and eight cats exhibiting grade 2 or grade 3 periodontal disease. Samples were cultivated on Wilkin Chalgrens agar and incubated in an anaerobic chamber for seven days. Selected anaerobic bacteria were isolated and identified to species level using 16S rRNA gene sequence analysis. Minimum inhibitory concentrations were determined for cefovecin and six additional antimicrobials using the agar dilution methodology recommended by the Clinical and Laboratory Standards Institute. The 65 clinical isolates were identified as Porphyromonas gulae (n = 45), Porphyromonas crevioricanis (n = 12), Porphyromonas macacae (n = 1), Porphyromonas cangingivalis (n = 1) Fusobacterium nucleatum (n = 2), Fusobacterium russii (n = 1) and Solobacterium moorei (n = 3). This is the first report of S. moorei being isolated from companion animals with periodontal disease. All isolates were highly susceptible to cefovecin, with a MIC90 of ≤0.125 μg/ml. Conversely, different resistance rates to ampicillin, amoxicillin and erythromycin between isolates were detected. Cefovecin is thus shown to be effective in vitro against anaerobic bacteria isolated from dogs and cats with periodontal disease.

Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Cat Diseases; Cats; Cephalosporins; Dental Plaque; DNA, Bacterial; DNA, Ribosomal; Dog Diseases; Dogs; Microbial Sensitivity Tests; Periodontal Diseases; RNA, Ribosomal, 16S; Sequence Analysis, DNA